drugset
drugset / Trial / NCT06214130

Bioavailability of Orfiril Long 500 mg Prolonged-Release Minitablets and Ergenyl Chrono 500 mg Prolonged-Release Tablets

NCT06214130 ↗

Phase 1 Completed 22 enrolled Desitin Arzneimittel GmbH BioPharma Services Inc. · collab
RandomizedCrossoverOpen-labelTreatment

Summary

Comparative bioavailability of valproate from Orfiril long 500 mg prolonged-release mini-tablets and Ergenyl chrono 500 mg prolonged-release tablets in healthy, male volunteers under fasting conditions.

Timeline

Start
2023-09-22
Primary completion
2023-11-06
Completion
2023-11-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Valproic Acid Small molecule 500 mg Oral

Indications

No indication recorded.